Novartis's $12 Billion Avidity Gamble Meets Clinical Reality as Three Pipeline Failures Rock the Stock

Novartis shares fell 10.9% after del-desiran missed its Phase III goal, the third clinical setback in a week and a blow to its $12 billion Avidity deal.

Three clinical disappointments in the space of a single week have cracked the narrative that Novartis builds its deal pipeline through discipline rather than impulse. The Basel-based drugmaker has long positioned itself as the pharmaceutical giant that buys with calculation, patiently offsetting expiring patents through acquisitions. That story now carries a visible fracture — and it runs straight through the company's most expensive wager.

The sequence began with a safety-driven halt. Novartis paused eight clinical studies involving its cell therapy rap-cel after three patients died from a severe immune reaction. Then came word that pelacarsen had missed the primary endpoint of the Phase III Lp(a)HORIZON trial on September 4, failing to reduce the risk of cardiovascular events. Reuters reported that US-listed shares slipped roughly 5% on that disclosure. The week's harshest blow landed on Tuesday, when del-desiran — a treatment for the rare muscle disorder myotonic dystrophy type 1 — also fell short of its primary goal in the Phase III HARBOR study. Reuters put that day's decline at about 11%, the worst single trading session in the company's history. CNBC labeled the del-desiran failure the third clinical setback in a week.

When the Priciest Takeover Becomes the Test Case

Del-desiran was never just another molecule in the portfolio. It sat at the core of the $12 billion acquisition of Avidity Biosciences, publicly touted by CEO Vas Narasimhan as a potential blockbuster. That is precisely what makes the miss so sensitive. The issue extends beyond lost revenue — Barclays analysts pegged the combined risk-adjusted peak potential of del-desiran and pelacarsen at around $5 billion. What is at stake is the credibility of an entire strategy: Novartis intends to compensate for shrinking patents through acquisitions.

When the flagship deal of that strategy stumbles against clinical reality, an uncomfortable question surfaces — can multibillion-dollar pharma takeovers ever be reliably modeled, or do they ultimately remain bets on biology that no contract can hedge? The market answered brutally on Tuesday. The stock plunged 10.9% to CHF 111.80, having set a record high of CHF 132.68 only on September 3. By the arithmetic, roughly CHF 24 billion in market capitalization evaporated within a handful of trading sessions.

The Technical Picture Reinforces the Damage

Measured in euros, the correction looks equally stark: the current price of EUR 120.10 sits a full 17% below the 52-week high. Over seven days the stock is down 14%, and over 30 days it has shed 11%. It also trades well beneath its 50-day moving average of EUR 134.07. An RSI of 32.9 points to oversold conditions — a purely technical signal that accompanies the fundamental unease rather than resolving it.

A separate reading of the same turbulence puts the stock about 12% below its level of 30 days ago and 18% under the 52-week high of EUR 144.30 reached back in February. An RSI of 29.3 confirms the oversold territory, while annualized volatility of 41% captures how jittery the market has become on this name. On a year-to-date basis, the shares are essentially flat — evidence of how thoroughly this one week has overshadowed the entire year.

Analyst reactions arrived predictably mixed. Deutsche Bank Research cut its price target on Wednesday from CHF 140 to CHF 120 and downgraded the stock from "Buy" to "Hold," a marked cooling of expectations. RBC Capital Markets rates the shares "Sector Perform" with a CHF 120 target, also as of Wednesday. Barclays had raised its target a day earlier from CHF 125 to CHF 130 but kept its "Equal Weight" rating, having already stripped pelacarsen from its model — while turning more optimistic on remibrutinib following positive news. Even amid the run of setbacks, the portfolio holds bright spots that soften the overall picture without reversing it.

Not Everything Went Wrong

On September 1, Novartis reported that remibrutinib, an oral treatment for multiple sclerosis, met its primary goals in two Phase III trials. The company now intends to file for global approvals and will present full data at a congress in Toronto in October. That does not offset the failed studies, but it demonstrates the pipeline is not failing across the board.

Operationally, too, there is movement. A deal with South Korean firm Alteogen worth up to $3.22 billion for access to its drug-delivery technology signals that Novartis continues investing in its future rather than merely playing defense. In parallel, the company is pushing ahead with restructuring: roughly 130 positions in Basel are to be cut as production and laboratories shift from the Kleinbasel site to the main campus. That is a cost measure, not a response to the trial setbacks — yet it shows the group working on efficiency at the same time.

The Sore Spot Remains Muscle Therapy

What troubles more than any single failure is the clustering. Reuters noted after the pelacarsen miss that pressure on the pipeline was mounting, since investors would now scrutinize further data on muscle therapies from the $12 billion Avidity Biosciences takeover especially closely. Del-desiran was exactly such a product from that acquisition — and its failure feeds doubts about the investment decision itself.

Novartis, for its part, is holding to its long-term revenue guidance, expecting annual growth of 5% to 6% through 2030. That is the real question this week raises: can a company whose last three studies failed carry that guidance on the strength of its remaining portfolio and future acquisitions alone? The pipeline will have to supply the answer — not the announcement itself. For the broader pharmaceutical industry, which increasingly leans on takeovers as a substitute for its own research successes, Novartis these days serves as a case study in how quickly a growth story can turn into a question of trust.